Cargando…

Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia

OBJECTIVES: Fosmanogepix (APX001), a first-in-class, intravenous (IV) and oral (PO) antifungal prodrug, is being developed to treat invasive fungal diseases (IFDs). Manogepix (APX001A; active moiety) targets fungal glycosylphosphatidylinositol-anchored cell wall transfer protein 1, inhibiting cell w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cornely, Oliver A, Ostermann, Helmut, Koehler, Philipp, Teschner, Daniel, Limburg, Endrik, Kramer, William G, Barbat, Sara H, Tawadrous, Margaret, Hodges, Michael R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631825/ https://www.ncbi.nlm.nih.gov/pubmed/37681450 http://dx.doi.org/10.1093/jac/dkad269

Ejemplares similares

Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers
por: Hodges, Michael R., et al.
Publicado: (2023)

Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial
por: Pappas, Peter G, et al.
Publicado: (2023)

Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris: Results from a Phase 2 Trial
por: Vazquez, Jose A., et al.
Publicado: (2023)

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
por: Hoenigl, Martin, et al.
Publicado: (2021)

1157. Clinical Safety, Efficacy, and Pharmacokinetics of Fosmanogepix, a Novel First-in-class Antifungal, in Patients with Renal Insufficiency: Subset Analysis from a Phase 2 Candidemia Trial
por: Bulpa, Pierre, et al.
Publicado: (2020)

147. Clinical Safety and Efficacy of Novel Antifungal, Fosmanogepix, in the Treatment of Candidemia: Results from a Phase 2 Proof of Concept Trial
por: Pappas, Peter, et al.
Publicado: (2020)

S4.1a Fusariosis: MICs, mono versus combination therapy and fosmanogepix
por: Hoenigl, Martin
Publicado: (2022)

Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2020)

726. APX001 (Fosmanogepix) Is Effective in an Immunosuppressed Mouse Model of Rhizopus oryzae Infection
por: Gebremariam, Teklegiorgis, et al.
Publicado: (2019)

Galactomannan Is a Biomarker of Fosmanogepix (APX001) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2019)

Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections
por: Shaw, Karen Joy, et al.
Publicado: (2020)

Pharmacokinetics of Four Tyrosine Kinase Inhibitors in Adult and Paediatric Chronic Myeloid Leukaemia Patients
por: Allegra, Sarah, et al.
Publicado: (2023)

Chemotherapy of the Myeloid Leukaemias
por: Stuart, John
Publicado: (1980)

Safety, Tolerability, and Pharmacokinetics (PK) of Posaconazole (POS) Intravenous (IV) Solution and Oral Powder for Suspension in Children With Neutropenia
por: Groll, Andreas H, et al.
Publicado: (2017)

Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma
por: Stemler, Jannik, et al.
Publicado: (2020)

Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis
por: Alkhazraji, Sondus, et al.
Publicado: (2020)

678. Galactomannan Is a Biomarker of APX001 (Fosmanogepix) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis
por: Gebremariam, Teklegiorgis, et al.
Publicado: (2019)

Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis
por: Wiederhold, Nathan P., et al.
Publicado: (2019)

The Combination Treatment of Fosmanogepix and Liposomal Amphotericin B Is Superior to Monotherapy in Treating Experimental Invasive Mold Infections
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2022)

Dose Schedule Optimization and the Pharmacokinetic Driver of Neutropenia
por: Patel, Mayankbhai, et al.
Publicado: (2014)

Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia
por: Ladikou, E. E., et al.
Publicado: (2020)

1558. A Population Pharmacokinetic Model for Posaconazole Intravenous Solution and Oral Powder for Suspension Formulations in Pediatric Patients With Neutropenia
por: Winchell, Gregory A, et al.
Publicado: (2019)

Novel lysine‐specific histone demethylase 1 inhibitor in acute myeloid leukaemia transformed from essential thrombocythaemia
por: Hodges, Samantha, et al.
Publicado: (2021)

Neutropenia during High Dose Intravenous Oxacillin Therapy
por: Ahern, Mary Jean, et al.
Publicado: (1976)

Erythropoiesis in Murine Myeloid Leukaemia
por: Tanaka, T.
Publicado: (1970)

Desacetylmethylcolchicine in the Treatment of Myeloid Leukaemia
por: Jelliffe, A. M., et al.
Publicado: (1956)

A Case of Myeloid Leukæmia
por: Ghosal, J. N.
Publicado: (1931)

Asciminib for chronic myeloid leukaemia
Publicado: (2022)

Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial
por: Drevin, Guillaume, et al.
Publicado: (2022)

Allelic Imbalance of Recurrently Mutated Genes in Acute Myeloid Leukaemia
por: Batcha, Aarif M. N., et al.
Publicado: (2019)

Human leukaemia: recent tissue culture studies on the nature of myeloid leukaemia.
por: Metcalf, D.
Publicado: (1973)

IL-8 as mediator in the microenvironment-leukaemia network in acute myeloid leukaemia
por: Kuett, Alexander, et al.
Publicado: (2015)

253. Febrile Neutropenia Antibiotic De-escalation Study in Acute Myeloid Leukemia Patients With Prolonged Neutropenia
por: Alegria, William, et al.
Publicado: (2018)

Targeting apoptosis in acute myeloid leukaemia
por: Cassier, Philippe A, et al.
Publicado: (2017)

Adhesion Deregulation in Acute Myeloid Leukaemia
por: Gruszka, Alicja M., et al.
Publicado: (2019)

Murine Models of Acute Myeloid Leukaemia
por: Almosailleakh, Marwa, et al.
Publicado: (2019)

Wnt Signalling in Acute Myeloid Leukaemia
por: Gruszka, Alicja M., et al.
Publicado: (2019)

Molecular Mechanisms and Therapies of Myeloid Leukaemia
por: Brown, Elliott, et al.
Publicado: (2022)

Chronic myeloid leukaemia with marked thrombocytosis
por: Ooi, Jun, et al.
Publicado: (2020)

372. Attributable Mortality of Candidemia After Introduction of Echinocandins
por: Cornely, Florian, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0uub13l86dab1dov3na3p1nb1i